


[ABOUT US](#)
[WHAT'S NEW](#)
[HEALTHCARE  
PROFESSIONALS](#)
[PATIENTS](#)
[PRODUCTS](#)
[CONTACT US](#)

Specialized therapies are our focus.  
Specialized service is our promise.



## Welcome to Three Rivers Pharmaceuticals

Three Rivers Pharmaceuticals® welcomes you to learn more about the company and its products. Established in 2000, Three Rivers Pharmaceuticals devotes its efforts and resources to developing, manufacturing, and marketing pharmaceutical therapies which are indicated for diseases/medical conditions requiring specialized treatment. Currently, Three Rivers Pharmaceuticals markets prescription drugs in both the U.S. and internationally, in the therapeutic categories of [antiviral](#) and [antifungal](#) agents.

The company has continued to grow its portfolio into the branded market with the acquisition of AMPHOTEC®/AMPHOCIL®. This product is currently approved and actively marketed in over 40 countries worldwide.

Three Rivers Pharmaceuticals has a strong presence in the Hepatitis C market with the launch of Ribasphere® Tablets and Ribasphere® RibaPak® (ribavirin, USP). The company expanded its Hepatitis C franchise with the acquisition of INFERGEN® from Valeant Corp. With the development and acquisition of these specialized therapies, Three Rivers Pharmaceuticals has helped many patients around the world improve the quality of their treatment.

[Business Opportunities](#)
[Employment Opportunities](#)

## IN THE NEWS

**7/6/10 | Three Rivers Pharmaceuticals Announces FDA Approval Of Expanded Labeling of INFERGEN®**

[More>>](#)

**6/29/10 | Three Rivers Pharmaceuticals announces FDA Approval of Anastrozole Tablets, 1 mg**

Three Rivers Pharmaceuticals, LLC has received the final approval from the U.S. Food and Drug Administration (FDA) to market Anastrozole Tablets, 1 mg.

[More>>](#)

## FACTS:

Chronic hepatitis C usually progresses at a very slow rate, often over a period of 10 to 30 years

